FORT WORTH, TX, April 05, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer..

德克萨斯州沃思堡，2024年4月5日（环球通讯社）--总部位于德克萨斯州沃思堡的Sanara MedTech Inc.今天宣布任命Jake Waldrop为首席运营官，Tyler Palmer为首席企业发展和战略官。Sanara MedTech Inc.是一家专注于开发和商业化变革技术以改善临床效果并减少外科、慢性伤口和皮肤护理市场的医疗保健支出的医疗技术公司（“Sanara”，“公司”，“我们”，“我们”或“我们”）（纳斯达克：SMTI）。。

Zach Fleming, Sanara's Chief Executive Officer, stated, “Jake and Tyler are seasoned executives with a wealth of experience in the medical device and wound care industries. We are excited for them to join the team and help us continue to build on the success we have had so far offering solutions that can improve clinical outcomes and reduce healthcare expenditures.”.

萨纳拉首席执行官扎克·弗莱明表示：“杰克和泰勒是经验丰富的高管，在医疗器械和伤口护理行业拥有丰富的经验。我们很高兴他们加入团队，帮助我们继续在迄今为止取得的成功基础上再接再厉，提供可以改善临床效果和减少医疗支出的解决方案。”。

Mr. Waldrop brings 20 years of experience leading cross functional teams through a multitude of business process transformations in the technology and medical device industries. Most recently Mr. Waldrop held the position of Chief Financial Officer for Trilliant Surgical, and after their sale to Enovis (formerly DJO) in early 2021, Jake held the position of Vice President of Finance and Integrations for the newly founded Foot and Ankle division of Enovis.

Waldrop先生拥有20年的经验，通过技术和医疗器械行业的众多业务流程变革，领导跨职能团队。最近，Waldrop先生担任Trilliant Surgical的首席财务官，并在2021年初将其出售给Enovis（前DJO）后，Jake担任Enovis新成立的足踝部财务和整合副总裁。

Mr. Waldrop’s career began in public accounting with KPMG, after which Jake has held Controller positions at 2 fast growing technology companies, The Planet and Alert Logic..

Waldrop先生的职业生涯始于毕马威会计师事务所（KPMG），之后Jake曾在两家快速发展的科技公司Planet and Alert Logic担任财务总监。。

Mr. Palmer brings extensive expertise in the healthcare sector, particularly in leading strategic growth and corporate development initiatives aimed at enhancing financial and clinical outcomes for providers, while maximizing shareholder returns. In his most recent role, Mr. Palmer served as the Senior Vice President of Corporate Development, Strategy, and Product at AQuity Solutions, a leading provider of outsourced revenue cycle and clinical documentation solutions.

帕尔默先生在医疗保健领域拥有广泛的专业知识，特别是在领先的战略增长和企业发展举措方面，旨在提高供应商的财务和临床成果，同时最大限度地提高股东回报。帕尔默先生最近担任AQuity Solutions公司的企业发展、战略和产品高级副总裁，AQuity Solutions是外包收入周期和临床文档解决方案的领先供应商。

Under his leadership, he crafted and executed a strategic vision that included multiple successful acquisitions and technology investments. Prior to this, Mr. Palmer held various leadership roles in corporate development, marketing, and business unit leadership across the Orthopedic, Surgical, and Wound Care sectors at Zimmer, BSN medical, and Essity..

在他的领导下，他制定并执行了一项战略愿景，其中包括多次成功收购和技术投资。在此之前，Palmer先生曾在Zimmer、BSN medical和Essity的骨科、外科和伤口护理部门担任公司开发、营销和业务部门领导职务。。

Mr. Waldrop’s appointment is effective April 15, 2024 and Mr. Palmer’s appointment was effective April 1, 2024.

Waldrop先生的任命于2024年4月15日生效，Palmer先生的任命于2024年4月1日生效。

About Sanara MedTech Inc.

关于Sanara MedTech Inc。

With a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute care settings and offers wound care and dermatology virtual consultation services via telemedicine.

Sanara MedTech Inc.专注于通过循证治疗解决方案改善患者预后，营销、分销和开发外科、伤口和皮肤护理产品，供医院、诊所和所有急性后护理机构的医生和临床医生使用，并通过远程医疗提供伤口护理和皮肤病虚拟咨询服务。

Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX® Surgical Activated Collagen®, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN™ Verified Inductive Bone Matrix, ALLOCYTE™ Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, TEXAGEN® Amniotic Membrane Allograft, and BIASURGE® Advanced Surgical Solution to the surgical market.

Sanara的产品主要在北美高级伤口护理和外科组织修复市场销售。Sanara销售和分销CellerateRX®外科活化胶原蛋白®、FORTIFY TRG®组织修复移植物和FORTIFY FLOWABLE®细胞外基质，以及一系列先进的生物产品，专注于ACTIGEN™验证的诱导性骨基质、ALLOCYTE™Plus先进的活骨基质、BiFORM®生物活性可模塑基质、TEXAGEN®羊膜同种异体移植物和BIASURGE®先进的外科手术解决方案。

In addition, the following products are sold in the wound care market: BIAKŌS® Antimicrobial Skin and Wound Cleanser, BIAKŌS® Antimicrobial Wound Gel, BIAKŌS® Antimicrobial Skin and Wound Irrigation Solution and HYCOL® Hydrolyzed Collagen. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates.

此外，以下产品在伤口护理市场上销售：BIAKŌS®抗菌皮肤和伤口清洁剂，BIAKŌS®抗菌伤口凝胶，BIAKŌS®抗菌皮肤和伤口冲洗液以及HYCOL®水解胶原蛋白。Sanara的管道还包含潜在的转化产品候选物，用于缓解机会性病原体和生物膜，伤口再上皮化和闭合，坏死组织清创和细胞相容性底物。

The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost..

该公司相信它有能力在满足质量和监管要求的同时，推动其从概念到临床前和临床开发的管道。萨纳拉一直在寻求长期战略合作伙伴关系，重点是以较低的总体成本改进成果的产品。。

Information about Forward-Looking Statements

关于前瞻性声明的信息

The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intend,” “may,” “plan,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions.

本新闻稿中不构成历史事实的声明是“前瞻性声明”，属于1995年《私人证券诉讼改革法案》所定义的安全港，并受其约束。这些陈述可以通过诸如“目标”、“预期”、“相信”、“沉思”、“继续”、“可能”、“估计”、“预期”、“预测”、“指导”、“打算”、“可能”、“计划”、“可能”、“潜在”、“预测”、“初步”、“项目”、“寻求”、“应该”、“目标”、“将要”或这些术语的否定、这些术语的变化或其他类似表达来识别。

These forward-looking statements include, among others, statements regarding the development of new products, the timing of commercialization of our products, the regulatory approval process and expansion of the Company’s business in telehealth and wound care. These items involve risks, contingencies and uncertainties such as Sanara’s ability to attract and retain key employees, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements..

这些前瞻性声明包括有关新产品开发、产品商业化时间、监管审批流程以及公司远程医疗和伤口护理业务扩展的声明。这些项目涉及风险、意外事件和不确定性，如萨纳拉吸引和留住关键员工的能力、产品需求程度、市场和客户接受程度、经济条件的影响、竞争、定价、与新产品开发和获得监管部门批准的过程相关的不确定性、完成和整合收购的能力，以及公司向美国证券交易委员会提交的文件中详述的其他风险、意外事件和不确定性，这些风险、意外事件和不确定性可能导致公司的实际经营成果、业绩或业务计划或前景与这些声明中表达或暗示的结果、业绩或业务计划或前景产生重大差异。。

All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.

所有前瞻性声明仅在作出之日起生效，公司没有义务修改任何此类声明以反映未来情况或意外事件的发生，适用证券法要求的除外。

Investor Contact:

投资者联系人：

Callon Nichols, Director of Investor Relations

Callon Nichols，投资者关系总监

713-826-0524

713-826-0524

CNichols@sanaramedtech.com

CNichols@sanaramedtech.com

SOURCE: Sanara MedTech Inc.

资料来源：Sanara MedTech Inc。